Figures & data
Notes: One hundred forty patients with HeFH and/or CVD (13% of the referred cohort) eligible for PCSK9 inhibitor therapy by US Food and Drug Administration and commercial insurance guidelines by virtue of LDLC on maximal-tolerated therapy >100 (dosage was MTDLLT, which included zero dose statin for those with statin intolerance).
Abbreviations: CVD, cardiovascular disease; HeFH, heterozygous familial hypercholesterolemia; LDLC, low-density lipoprotein cholesterol; MTDLLT, maximal-tolerated dose of standard-of-care LDL cholesterol-lowering therapy; PCSK9, proprotein convertase subtilisin/kexin type 9.
Abbreviations: CVD, cardiovascular disease; HeFH, heterozygous familial hypercholesterolemia; LDLC, low-density lipoprotein cholesterol; MTDLLT, maximal-tolerated dose of standard-of-care LDL cholesterol-lowering therapy; PCSK9, proprotein convertase subtilisin/kexin type 9.